Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCL3 | P20749 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18216276 | 0.92 | MAPT (0.42) | KMT2ASMN1; SMN2PDE4BEPHX2CHRM4 | |
| SCHEMBL20205264 | 0.91 | CHRM4 (0.38) | LMNAKMT2ASMN1; SMN2BCL3PDE4B | |
| SCHEMBL18216319 | 0.91 | CHRM4 (0.39) | PDE4BCNR1CNR2CHRM4 | |
| SCHEMBL18216475 | 0.88 | CHRM4 (0.36) | KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL20205221 | 0.87 | POLB (0.44) | KMT2ACHRM4 | |
| SCHEMBL20201143 | 0.87 | HPGD (0.43) | KMT2ASMN1; SMN2EPHX2CHRM4 | |
| SCHEMBL20201142 | 0.85 | HPGD (0.49) | KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL20205084 | 0.85 | HPGD (0.42) | KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL18216473 | 0.85 | HPGD (0.43) | KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL20201145 | 0.84 | HPGD (0.41) | LMNAKMT2ASMN1; SMN2MAPK14CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | LMNA 423/4885KMT2A 3502/4885SMN1; SMN2 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.